Inhibitors of ERAP1 or ERAP2 to modulate antigen processing towards new psoriasis treatment
Grantee: Rebecca Deprez-Poulain, Professor, Institut Pasteur de Lille
Amount: DKK 3,190,714
Grant category: Research Grants in open competition
Year: 2024
Geography: France
Rebecca Deprez-Poulain’s project aims to investigate the therapeutic potential of ERAP1 and ERAP2 inhibitors for the treatment of psoriasis.
Psoriasis is caused by the erroneous recognition by T-cells of the immune system of self-peptides called antigens presented at the cell surface by the HLA-C receptor. This results in destruction cells and subsequent chronic inflammation. ERAP enzymes, which are the main actors of antigen preparation within cells, influence the immune response, and genetic studies show that several ERAP variants predispose to psoriasis. Rebecca Deprez-Poulain has identified selective inhibitors of ERAP1 and ERAP2 which decrease antigen presentation and T-cell activation and show preliminary positive results in vivo. Her project will combine structural biology, medicinal chemistry, biochemistry, and cellular biology to optimize current compounds into potent and selective inhibitors targeting ERAP. It will assess their therapeutic potential in purposely designed transgenic mouse models containing human ERAP, as well as in patient cells.
Rebecca Deprez-Poulain’s project may define the optimal profile of an ERAP inhibitor as a pharmacological tool, providing a foundation for the exploration of ERAP roles and eventually an ERAP-based oral treatment for psoriasis.
A novel model to study aging of skin immunity
Grantee: Nicolas Manel, Research Director, Institute Curie
Amount: DKK 2,723,700
Grant category: Research Grants in open competition
Year: 2024
Geography: France
Nicolas Manel’s project explores the mechanisms of skin aging and immunity dysfunction, with a focus on establishing a novel model for investigating the role of the nuclear envelope in skin aging.
Genome instability is considered a central mechanism of aging. The nuclear envelope is essential for genome stability. Nicolas Manel’s laboratory recently reported that in mice deficient for a protein of the nuclear envelope in the immune system, alveolar macrophages, but not other lung immune cells, acquire aging hallmarks and decline in number, as observed in chronological aging. This established that deficiency of a nuclear envelope component can represent a cell-intrinsic model of accelerated aging in specific immune cell types. In preliminary results, further explorations revealed that subsets of skin immune cells are also decreased in a mouse model of nuclear envelope deficiency. Interestingly, the same skin immune cells are decreased in the aged skin of humans and mice. Nicolas Manel’s project will test the hypothesis that loss of nuclear envelope integrity is a mechanism of aging in these skin immune cells. It aims to define the mechanisms leading to skin immune cell depletion, the impact on the immune cell homeostasis in the skin, and the pathophysiological consequences of such depletion in skin immunity against age-related pathologies.
The results of the project have the potential to reveal new fundamental pathways in the aging of skin immunity and its impact on the health of aged individuals.